<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143105">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02141984</url>
  </required_header>
  <id_info>
    <org_study_id>P14-362</org_study_id>
    <nct_id>NCT02141984</nct_id>
  </id_info>
  <brief_title>Surveillance of Humira in Korean JIA Patients</brief_title>
  <official_title>Post-Marketing Surveillance of Humira Injection in Korean JIA Patients Under the New-Drug Re-examination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 600 pediatric patients prescribed Humira Injection in usual practice according
      to the approved Korean product label will be registered into this observational study.
      Baseline data will be obtained at enrollment including demographics, underlying diseases and
      complications especially in regard to purified protein derivative (PPD) skin test, chest
      X-ray. At routine visits for Humira Injection administration which will occur according to
      usual medical practice, concomitant medication information and adverse events information
      will be collected for up to 70 days after the last administration of Humira.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Subjects with Adverse Events</measure>
    <time_frame>Up to 70 days following the last scheduled administration of Humira Injection, an expected average of 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Active Joint Count</measure>
    <time_frame>From the first administration (Day 1) to approximately 12weeks (±4weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Active Joint Count will be assessed and collected by participated investigators in routine medical practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment of the disease</measure>
    <time_frame>At approximately 12 weeks (±4weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's global assessment of the disease will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent's global assessment for effectiveness</measure>
    <time_frame>At approximately 12 weeks (±4weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parent's global assessment for effectiveness will be measured.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Polyarticular Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Polyarticular juvenile idiopathic arthritis patients</arm_group_label>
    <description>Polyarticular JIA patients between 4-17 age whom the response to previous disease-modifying anti rheumatic drug therapy has been inadequate</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        General hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who were diagnosed with polyarticular juvenile idiopathic arthritis(JIA) and
             were prescribed Humira by their physician according to the local label.

          2. Polyarticular juvenile idiopathic arthritis (JIA) patients for whom the response to
             previous disease-modifying anti rheumatic drug therapy has been inadequate

          3. Patients who give written authorization form to use their personal and health data
             from legal parents or representative.

        Physician will refer to the product market authorization (label) for inclusion criteria.

        Exclusion Criteria:

          1. Patients with known hypersensitivity to Humira or any of its excipients.

          2. Patients who is participating on other clinical trials. Physician will refer to the
             product market authorization (label) for exclusion criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah  Chee, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EunJung  Gu</last_name>
    <phone>+82 2 3429 9399</phone>
    <email>eunjung.gu@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SuKyung   Kim</last_name>
    <phone>+82 2 3429 9235</phone>
    <email>sukyung.kim@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126665</name>
      <address>
        <city>Anyang-si</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126665</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126675</name>
      <address>
        <city>Chungju-si</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126675</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126674</name>
      <address>
        <city>Daejeon</city>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126674</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126672</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126672</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126671</name>
      <address>
        <city>Gwangju</city>
        <zip>501-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126671</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126673</name>
      <address>
        <city>Jeonju-si</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126673</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126667</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126667</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126666</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126666</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126668</name>
      <address>
        <city>Yangsan-si</city>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126668</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126670</name>
      <address>
        <city>Yangsan-si</city>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126670</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korean regulatory required Postmarketing Surveillance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
